Anti-centromere antibodies (ACA) are autoantibodies that target centromeric proteins, primarily associated with systemic sclerosis (scleroderma), particularly the limited form. Their presence is clinically significant as it can aid in the diagnosis of scleroderma and is linked to specific clinical features, such as skin involvement and pulmonary complications. Understanding ACA status helps guide management and prognostication in affected patients.